MUC5B promoter polymorphism and interstitial lung abnormalities

Gary M Hunninghake1, Hiroto Hatabu, Yuka Okajima

  • 1Pulmonary and Critical Care Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA. ghunninghake@partners.org

Abstract

Insights

A common MUC5B gene variant (rs35705950) is linked to interstitial lung disease in the general population. This association is stronger in older individuals but not affected by smoking.

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Radiology

Background:

  • A common MUC5B promoter polymorphism (rs35705950) is linked to idiopathic pulmonary fibrosis.
  • The association of this polymorphism with interstitial lung disease (ILD) in the general population remains unclear.

Purpose of the Study:

  • To investigate the association between the MUC5B rs35705950 polymorphism and interstitial lung abnormalities in the general population.
  • To determine if factors like age and smoking influence this association.

Main Methods:

  • Volumetric chest computed tomography (CT) was used to assess interstitial lung abnormalities in 2633 Framingham Heart Study participants.
  • Participants' genotypes at the rs35705950 locus were analyzed in relation to CT findings.

Main Results:

  • Interstitial lung abnormalities were detected in 7% of participants and were associated with shortness of breath, chronic cough, and reduced lung function.
  • Each copy of the minor rs35705950 allele increased the odds of interstitial lung abnormalities by 2.8 times and definite pulmonary fibrosis by 6.3 times.
  • The association was stronger in individuals over 50, but not influenced by smoking history.

Conclusions:

  • The MUC5B promoter polymorphism (rs35705950) is associated with interstitial lung disease in the general population.
  • This association is more pronounced in older individuals and independent of smoking status.

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...